# Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK3328 (MK-3328-001)

> **NCT00954538** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 19 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** [18F]MK-3328

## Key facts

- **NCT ID:** NCT00954538
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2015-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00954538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00954538, "Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK3328 (MK-3328-001)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00954538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*